Medexus Pharmaceuticals Inc.
MEDXF
$2.39
$0.104.15%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 99.43M | 104.10M | 105.66M | 108.33M | 109.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.43M | 104.10M | 105.66M | 108.33M | 109.54M |
| Cost of Revenue | 36.44M | 40.15M | 42.21M | 44.82M | 46.13M |
| Gross Profit | 63.00M | 63.95M | 63.45M | 63.51M | 63.41M |
| SG&A Expenses | 47.47M | 47.23M | 45.00M | 43.18M | 41.38M |
| Depreciation & Amortization | 9.71M | 9.05M | 8.19M | 7.18M | 6.19M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.55M | 98.11M | 97.22M | 96.41M | 94.50M |
| Operating Income | 3.89M | 5.99M | 8.44M | 11.92M | 15.04M |
| Income Before Tax | -25.00K | 409.00K | 155.00K | 1.44M | 3.19M |
| Income Tax Expenses | 247.00K | 28.00K | -651.00K | -807.00K | -373.00K |
| Earnings from Continuing Operations | -0.27 | 0.38 | 0.81 | 2.25 | 3.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -272.00K | 381.00K | 806.00K | 2.25M | 3.56M |
| EBIT | 3.89M | 5.99M | 8.44M | 11.92M | 15.04M |
| EBITDA | 13.56M | 15.00M | 16.59M | 19.06M | 21.08M |
| EPS Basic | -0.01 | 0.02 | 0.03 | 0.10 | 0.15 |
| Normalized Basic EPS | 0.01 | 0.02 | 0.07 | 0.13 | 0.20 |
| EPS Diluted | -0.01 | 0.02 | 0.03 | 0.10 | 0.15 |
| Normalized Diluted EPS | 0.01 | 0.02 | 0.07 | 0.13 | 0.20 |
| Average Basic Shares Outstanding | 126.58M | 118.83M | 111.09M | 103.29M | 98.13M |
| Average Diluted Shares Outstanding | 126.58M | 118.83M | 111.94M | 104.14M | 98.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |